Joshua Ray Jimenez, MD
Internal Medicine · Skaneateles, NYNPI 1437612942
Payments from drug & device makers
Across 153 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$633
- AstraZeneca$362
- Novo Nordisk$331
- Gilead$287
- Pfizer$266
- AbbVie$254
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,540100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 18 | $633 |
| AstraZeneca | 12 | $362 |
| Novo Nordisk | 21 | $331 |
| Gilead | 5 | $287 |
| Pfizer | 17 | $266 |
| AbbVie | 17 | $254 |
| Boehringer Ingelheim | 4 | $155 |
| Exact Sciences | 7 | $126 |
| Madrigal Pharmaceuticals | 5 | $119 |
| Lilly USA, LLC | 7 | $111 |
| Pulmonx Corporation | 1 | $96 |
| Johnson & Johnson | 4 | $72 |
| Intuitive Surgical | 1 | $59 |
| Bayer | 4 | $58 |
| Amgen | 3 | $56 |
| Astellas Pharma US Inc | 2 | $51 |
| Viiv Healthcare Company | 2 | $42 |
| Merck | 2 | $40 |
| Hologic Sales And Service, LLC | 2 | $39 |
| Sanofi-aventis U.S. LLC | 1 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Theratechnologies Inc. | 1 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Shield Therapeutics Inc | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Indivior Inc. | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Mirum Pharmaceuticals, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Abbott | 1 | $15 |
| Novartis | 1 | $14 |
| Corium, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,540 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CholbamCholic Acid | 11 | $247,653 |
| JardianceEmpagliflozin | 127 | $158,226 |
| OzempicSemaglutide | 83 | $140,065 |
| TrulicityDulaglutide | 55 | $85,801 |
| EliquisApixaban | 57 | $80,370 |
| JanuviaSitagliptin Phosphate | 32 | $47,133 |
| MounjaroTirzepatide | 18 | $37,696 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $34,400 |
| FarxigaDapagliflozin Propanediol | 13 | $21,870 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $18,517 |
| XareltoRivaroxaban | 11 | $17,871 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $17,340 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $8,279 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $6,599 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $6,162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mirum Pharmaceuticals, Inc.Cholbam | $27 | $247,65311 claims |
| Boehringer IngelheimJardiance | $155 | $158,226127 claims |
| Novo NordiskOzempic | $331 | $140,06583 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $111 | $123,49673 claims |
| PfizerEliquis, Paxlovid | $266 | $84,49775 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $362 | $47,48949 claims |
| MerckJanuvia | $40 | $47,13332 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $633 | $24,67942 claims |
| Johnson & JohnsonXarelto | $72 | $17,87111 claims |
| Astellas Pharma US IncMyrbetriq | $51 | $5,82511 claims |
| AbbVieSynthroid | $254 | $2,75028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Skaneateles
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.